Cargando…
The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure
Background: adropin plays a protective role in cardiac remodeling through supporting energy metabolism and water homeostasis and suppressing inflammation. Low circulating levels of adropin were positively associated with the risk of cardiovascular diseases and type 2 diabetes mellitus (T2DM). We hyp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953100/ https://www.ncbi.nlm.nih.gov/pubmed/36830993 http://dx.doi.org/10.3390/biomedicines11020457 |
_version_ | 1784893794174369792 |
---|---|
author | Berezin, Alexander A. Obradovic, Zeljko Fushtey, Ivan M. Berezina, Tetiana A. Novikov, Evgen V. Schmidbauer, Lukas Lichtenauer, Michael Berezin, Alexander E. |
author_facet | Berezin, Alexander A. Obradovic, Zeljko Fushtey, Ivan M. Berezina, Tetiana A. Novikov, Evgen V. Schmidbauer, Lukas Lichtenauer, Michael Berezin, Alexander E. |
author_sort | Berezin, Alexander A. |
collection | PubMed |
description | Background: adropin plays a protective role in cardiac remodeling through supporting energy metabolism and water homeostasis and suppressing inflammation. Low circulating levels of adropin were positively associated with the risk of cardiovascular diseases and type 2 diabetes mellitus (T2DM). We hypothesized that sodium–glucose linked transporter 2 (SGLT2) inhibitor dapagliflosin might represent cardiac protective effects in T2DM patients with known chronic HF through the modulation of adropin levels. Methods: we prospectively enrolled 417 patients with T2DM and HF from an entire cohort of 612 T2DM patients. All eligible patients were treated with the recommended guided HF therapy according to their HF phenotypes, including SGLT2 inhibitor dapagliflozin 10 mg, daily, orally. Anthropometry, clinical data, echocardiography/Doppler examinations, and measurements of biomarkers were performed at the baseline and over a 6-month interval of SGLT2 inhibitor administration. Results: in the entire group, dapagliflozin led to an increase in adropin levels by up to 26.6% over 6 months. In the female subgroup, the relative growth (Δ%) of adropin concentrations was sufficiently higher (Δ% = 35.6%) than that in the male subgroup (Δ% = 22.7%). A multivariate linear regression analysis of the entire group showed that the relative changes (Δ) in the left ventricular (LV) ejection fraction (LVEF), left atrial volume index (LAVI), and E/e’ were significantly associated with increased adropin levels. In the female subgroup, but not in the male subgroup, ΔLVEF (p = 0.046), ΔLAVI (p = 0.001), and ΔE/e’ (p = 0.001) were independent predictive values for adropin changes. Conclusion: the levels of adropin seem to be a predictor for the favorable modification of hemodynamic performances during SGLT2 inhibition, independent ofN-terminal brain natriuretic pro-peptide levels. |
format | Online Article Text |
id | pubmed-9953100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99531002023-02-25 The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure Berezin, Alexander A. Obradovic, Zeljko Fushtey, Ivan M. Berezina, Tetiana A. Novikov, Evgen V. Schmidbauer, Lukas Lichtenauer, Michael Berezin, Alexander E. Biomedicines Article Background: adropin plays a protective role in cardiac remodeling through supporting energy metabolism and water homeostasis and suppressing inflammation. Low circulating levels of adropin were positively associated with the risk of cardiovascular diseases and type 2 diabetes mellitus (T2DM). We hypothesized that sodium–glucose linked transporter 2 (SGLT2) inhibitor dapagliflosin might represent cardiac protective effects in T2DM patients with known chronic HF through the modulation of adropin levels. Methods: we prospectively enrolled 417 patients with T2DM and HF from an entire cohort of 612 T2DM patients. All eligible patients were treated with the recommended guided HF therapy according to their HF phenotypes, including SGLT2 inhibitor dapagliflozin 10 mg, daily, orally. Anthropometry, clinical data, echocardiography/Doppler examinations, and measurements of biomarkers were performed at the baseline and over a 6-month interval of SGLT2 inhibitor administration. Results: in the entire group, dapagliflozin led to an increase in adropin levels by up to 26.6% over 6 months. In the female subgroup, the relative growth (Δ%) of adropin concentrations was sufficiently higher (Δ% = 35.6%) than that in the male subgroup (Δ% = 22.7%). A multivariate linear regression analysis of the entire group showed that the relative changes (Δ) in the left ventricular (LV) ejection fraction (LVEF), left atrial volume index (LAVI), and E/e’ were significantly associated with increased adropin levels. In the female subgroup, but not in the male subgroup, ΔLVEF (p = 0.046), ΔLAVI (p = 0.001), and ΔE/e’ (p = 0.001) were independent predictive values for adropin changes. Conclusion: the levels of adropin seem to be a predictor for the favorable modification of hemodynamic performances during SGLT2 inhibition, independent ofN-terminal brain natriuretic pro-peptide levels. MDPI 2023-02-04 /pmc/articles/PMC9953100/ /pubmed/36830993 http://dx.doi.org/10.3390/biomedicines11020457 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Berezin, Alexander A. Obradovic, Zeljko Fushtey, Ivan M. Berezina, Tetiana A. Novikov, Evgen V. Schmidbauer, Lukas Lichtenauer, Michael Berezin, Alexander E. The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure |
title | The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure |
title_full | The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure |
title_fullStr | The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure |
title_full_unstemmed | The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure |
title_short | The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure |
title_sort | impact of sglt2 inhibitor dapagliflozin on adropin serum levels in men and women with type 2 diabetes mellitus and chronic heart failure |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953100/ https://www.ncbi.nlm.nih.gov/pubmed/36830993 http://dx.doi.org/10.3390/biomedicines11020457 |
work_keys_str_mv | AT berezinalexandera theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT obradoviczeljko theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT fushteyivanm theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT berezinatetianaa theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT novikovevgenv theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT schmidbauerlukas theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT lichtenauermichael theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT berezinalexandere theimpactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT berezinalexandera impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT obradoviczeljko impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT fushteyivanm impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT berezinatetianaa impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT novikovevgenv impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT schmidbauerlukas impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT lichtenauermichael impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure AT berezinalexandere impactofsglt2inhibitordapagliflozinonadropinserumlevelsinmenandwomenwithtype2diabetesmellitusandchronicheartfailure |